Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PPM1B | O75688 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4157000 | 1.00 | LMNA (0.60) | LMNAALOX15ALDH1A1HSD17B10CYP1A2 | |
| SCHEMBL30485854 | 0.91 | LMNA (0.58) | LMNAALOX15ALDH1A1HSD17B10CYP1A2 | |
| SCHEMBL9861951 | 0.91 | LMNA (0.58) | LMNAALOX15ALDH1A1HSD17B10CYP1A2 | |
| SCHEMBL1261673 | 0.91 | LMNA (0.53) | LMNAALOX15ALDH1A1HSD17B10CYP1A2 | |
| SCHEMBL11010327 | 0.86 | LMNA (0.49) | LMNAALOX15ALDH1A1HSD17B10CYP1A2 | |
| SCHEMBL11007743 | 0.86 | LMNA (0.49) | LMNAALOX15ALDH1A1HSD17B10CYP1A2 | |
| SCHEMBL7641506 | 0.86 | LMNA (0.56) | LMNAALOX15ALDH1A1HSD17B10MGAM | |
| SCHEMBL11273588 | 0.84 | LMNA (0.47) | LMNAALOX15ALDH1A1HSD17B10CYP1A2 | |
| SCHEMBL11312999 | 0.84 | LMNA (0.47) | LMNAALOX15ALDH1A1HSD17B10CYP1A2 | |
| SCHEMBL11314101 | 0.84 | LMNA (0.47) | LMNAALOX15ALDH1A1HSD17B10CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222240-B2 | Use of substituted cyclopropane acid derivatives for producing drugs for use in the treatment of metabolic syndrome | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-07-17 | — | — | US | disclosed |
| US-20090088474-A1 | USE OF SUBSTITUTED CYCLOPROPANE ACID DERIVATIVES FOR PRODUCING DRUGS FOR USE IN THE TREATMENT OF METABOLIC SYNDROME | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-04-02 | — | — | US | disclosed |
| US-20080045590-A1 | USE OF SUBSTITUTED CYCLOPROPANE ACID DERIVATIVES FOR PRODUCING DRUGS FOR USE IN THE TREATMENT OF METABOLIC SYNDROME | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045590-A1 | USE OF SUBSTITUTED CYCLOPROPANE ACID DERIVATIVES FOR PRODUCING DRUGS FOR USE IN THE TREATMENT OF METABOLIC SYNDROME | CYP27A1, CYP11B2, CYP11B1 | LMNA 3703/4885ALOX15 642/4885ALDH1A1 401/4885 |
| US-20090088474-A1 | USE OF SUBSTITUTED CYCLOPROPANE ACID DERIVATIVES FOR PRODUCING DRUGS FOR USE IN THE TREATMENT OF METABOLIC SYNDROME | FFAR1, FFAR2, FFAR3 | LMNA 3135/4885ALOX15 321/4885ALDH1A1 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.